Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent
Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent is a paper indexed in PICO Portal from OpenAlex.
How many citations does Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent have?
Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent has 23 citations in the OpenAlex counts PICO Portal stores.
When was Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent published?
Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent has 2023 year in the PICO Portal index.
What is the open-access status of Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent?
Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent has hybrid oa status in the PICO Portal index.
What is the DOI of Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent?
The DOI for Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent is on the source record.
What is the PMID of Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent?
The PMID for Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent is on the source record.
What is the OpenAlex record for Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent?
The OpenAlex for Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent is on the source record.